Global Roadmap for research and development for tuberculosis (TB) vaccines

About this consultation

Consultation period

27 December 2020 – 15 February 2021

Topic

Global Roadmap for research and development for tuberculosis (TB) vaccines

Target group

Global stakeholders such as researchers, funders, industry, regulatory and policy decision makers as well as individuals.

Objective of the consultation

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public-public partnership between 16 African and 14 European countries. EDCTP aims to support collaborative research that accelerates the clinical development of new or improved medical interventions (drugs, vaccines, microbicides and diagnostics) to prevent or treat HIV, TB, malaria and neglected infectious diseases in sub-Saharan Africa. EDCTP funds mainly clinical trials in sub-Saharan Africa, but also supports relevant individual, institutional, national and regional capacities for clinical research as well as research ethics review in sub-Saharan countries.

EDCTP has commissioned the Amsterdam Institute for Global Health and Development as a contractor to develop a Global Roadmap for research and development for tuberculosis (TB) vaccine. The roadmap intents to provide global stakeholders such as researchers, funders, industry, regulatory and policy decision makers with key actionable priorities that could help guide their actions. The Roadmap lists both the short-term objectives as well as the long-term strategic objectives for global TB vaccine development. The Roadmap focuses on developing and delivering affordable and effective vaccines for use in low- and middle-income countries where the vast majority of people affected by TB are concentrated.

Consultation process and outcome

The process for developing this Roadmap consists of several steps: desk review and stakeholder inventory, in-depth interviews with selected stakeholders, a consent workshop and various rounds of stakeholder consultation on the subsequent draft versions of the Roadmap. These rounds of consultation included both targeted requests for feedback to selected stakeholders and the current public consultation. The contributions of this public consultation will be used to complete the final version of the Global Roadmap.

Contributions

Geir Mathiesen /Norwegian University of Life Sciences
Maite Suarez /IAVI
Carlos Martin/ University of Zaragoza
Innocent Ali /Senior Lecturer-Researcher at the University of Dschang, Cameroon
SILVANA SPINDOLA MIRANDA/ UNIVERSIDADE FEDERAL DE MINAS GERAIS, BRAZIL